KR940007002A - (s)-(+)- 하이드록시 클로로퀸 - Google Patents

(s)-(+)- 하이드록시 클로로퀸 Download PDF

Info

Publication number
KR940007002A
KR940007002A KR1019930018519A KR930018519A KR940007002A KR 940007002 A KR940007002 A KR 940007002A KR 1019930018519 A KR1019930018519 A KR 1019930018519A KR 930018519 A KR930018519 A KR 930018519A KR 940007002 A KR940007002 A KR 940007002A
Authority
KR
South Korea
Prior art keywords
hydroxychloroquine
hydroxy chloroquine
pharmaceutically acceptable
treatment
lupus erythematosus
Prior art date
Application number
KR1019930018519A
Other languages
English (en)
Inventor
조안나 스티쳐 베라
프란시스 미크네 윌리엄
Original Assignee
폴이. 듀퐁
스터얼링 윈드롭 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 폴이. 듀퐁, 스터얼링 윈드롭 아이엔씨. filed Critical 폴이. 듀퐁
Publication of KR940007002A publication Critical patent/KR940007002A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Detergent Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

본원은 (R)-(-)-하이드록시 클로로퀀을 실질적으로 함유치아니하는 (S)-(+)-하이드록시 클로로퀸 또는 이의 제약학적으로 허용되는 산부가염 및 말라리아, 홍반성 낭창 또는 류마티스성 관절염 치료에 유효한 양의, 상기 (S)-(+)-하이드록시 클로로퀸 또는 이의 제약학적으로 허용되는 산부가염 및 제약학적으로 허용되는 비클(vehicle)로 구성되는 인체내 말라리아, 홍반성 낭창 또는 류마티스성 관절염 치료용 조성물을 제공한다.

Description

(S)-(+)-하이드록시 클로로퀸
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (2)

  1. (R)-(-)-하이드록시 클로로퀀을 실질적으로 함유치아니하는 (S)-(+)-하이드록시 클로로퀸 또는 이의 제약학적으로 허용되는 산부가염.
  2. 제약학적으로 허용되는 비클(vehicle) 및 말라리아, 홍반성 낭창 또는 류마티스성 관절염 치료에 유효한 양의 제1항(S)-(+)-하이드록시 클로로퀸으로 구성된 인체내 말라리아, 홍반성낭창 또는 류마티스성 관절염 치료용 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930018519A 1992-09-15 1993-09-15 (s)-(+)- 하이드록시 클로로퀸 KR940007002A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92-945032 1992-09-15
US07/945,032 US5314894A (en) 1992-09-15 1992-09-15 (S)-(+)-hydroxychloroquine

Publications (1)

Publication Number Publication Date
KR940007002A true KR940007002A (ko) 1994-04-26

Family

ID=25482508

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930018519A KR940007002A (ko) 1992-09-15 1993-09-15 (s)-(+)- 하이드록시 클로로퀸

Country Status (18)

Country Link
US (1) US5314894A (ko)
EP (1) EP0588430B1 (ko)
JP (1) JPH06199801A (ko)
KR (1) KR940007002A (ko)
AT (1) ATE166646T1 (ko)
AU (2) AU4732693A (ko)
CA (1) CA2104903A1 (ko)
CZ (1) CZ192393A3 (ko)
DE (1) DE69318783D1 (ko)
FI (1) FI934051A (ko)
HU (1) HUT70025A (ko)
IL (1) IL107004A0 (ko)
MX (1) MX9305621A (ko)
MY (1) MY109822A (ko)
NO (1) NO180677C (ko)
NZ (1) NZ248671A (ko)
PH (1) PH30153A (ko)
SK (1) SK98793A3 (ko)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453431A (en) * 1993-10-29 1995-09-26 Gilman; Andrew L. Use of hydroxychloroquine for treatment of graft-versus-host disease
US6512010B1 (en) * 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US20040229908A1 (en) * 1999-07-13 2004-11-18 Jodi Nelson Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias
US20020198231A1 (en) * 1999-07-13 2002-12-26 Jodi Nelson Compositions and methods for the treatment of Parkinson's disease
US6916627B2 (en) * 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
US7108992B2 (en) * 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
WO2005062723A2 (en) * 2003-11-24 2005-07-14 Ipca Laboratories Limited An improved process for the preparation of 7-chloro-4-(5-n-ehtyl-n-2-hydroxyethylamine)-2-pentyl] aminoquinoline and its intermediates
KR101115412B1 (ko) 2008-09-08 2012-06-12 주식회사 대희화학 하이드록시클로로퀸의 신규 제조방법
KR101208587B1 (ko) * 2009-06-24 2012-12-06 여오영 하이드록시클로로퀸을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물
MX2013000242A (es) 2010-06-24 2014-04-14 Panmed Ltd Tratamiento de enfermedades relacionadas con el virus de hepatitis c que usa hidroxicloroquina o una combinacion de hidroxicloroquina y un agente antiviral.
EP2723337A1 (en) 2011-06-23 2014-04-30 Panmed Ltd. Treatment of hepatitis c virus
EP2561868A1 (en) 2011-08-24 2013-02-27 Anton Bernhard Van Oosten Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field
WO2014122537A2 (en) 2013-02-05 2014-08-14 Genoscience Sa Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
CN105693606B (zh) * 2016-03-09 2017-12-05 西安科技大学 一种光学纯(r)/(s)‑羟氯喹的不对称合成方法
CN105693605B (zh) * 2016-03-09 2017-12-22 西安科技大学 一种光学纯(r)/(s)‑氯喹的不对称合成方法
CN110283121A (zh) * 2019-08-06 2019-09-27 华东理工大学 羟氯喹的合成方法
CN113350344A (zh) * 2020-03-06 2021-09-07 华南理工大学 左旋手性磷酸氯喹在制备治疗冠状病毒药物中的应用
CN113350343A (zh) * 2020-03-06 2021-09-07 华南理工大学 右旋手性磷酸氯喹在制备治疗冠状病毒药物中的应用
EP4135673A4 (en) * 2020-04-14 2024-05-08 Glanis Pharmaceuticals, Inc. TRANSDERMAL AND/OR TOPICAL ADMINISTRATION SYSTEM COMPRISING HYDROXYCHLOROQUINE AND/OR CHLOROQUINE
US20230139565A1 (en) * 2020-04-20 2023-05-04 Glanis Pharmaceuticals, Inc. Oral delivery system comprising hydroxychloroquine and/or chloroquine
TWI845802B (zh) * 2020-04-21 2024-06-21 健亞生物科技股份有限公司 硫酸羥氯喹之晶體
WO2021217574A1 (en) * 2020-04-30 2021-11-04 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Treatment or prevention of coronaviridae infection
US20210369699A1 (en) 2020-05-31 2021-12-02 Genovate Biotechnology Co. Ltd. Treatment of lupus erythematosus using s-hydroxychloroquine
CN111909087A (zh) * 2020-06-15 2020-11-10 珠海润都制药股份有限公司 一种手性氨基氯喹啉的制备方法
CN111803501B (zh) * 2020-06-17 2022-10-18 南方科技大学 手性氯喹羟氯喹作为降低心脏毒性的用途
CN111793026A (zh) * 2020-07-23 2020-10-20 珠海润都制药股份有限公司 一种硫酸羟氯喹及其对映体的晶型和制备方法
CN114057640A (zh) * 2020-08-05 2022-02-18 凯特立斯（深圳）科技有限公司 一种光学纯(r)/(s)-羟氯喹侧链的不对称合成方法
CN112505198A (zh) * 2020-12-29 2021-03-16 珠海润都制药股份有限公司 一种s-硫酸羟氯喹异构体检验方法
JP2024520741A (ja) * 2021-06-04 2024-05-24 ジェノベート バイオテクノロジー カンパニー リミテッド Ｓ－ヒドロキシクロロキンを用いた抗リン脂質症候群の処置
CN114573464A (zh) * 2022-03-02 2022-06-03 重庆南松凯博生物制药有限公司 一种羟氯喹侧链精制方法
CN115089584A (zh) * 2022-06-14 2022-09-23 广州惠善医疗技术有限公司 手性羟氯喹或其药学上可接受的盐在制备防诊治免疫疾病药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2546658A (en) * 1949-07-23 1951-03-27 Sterling Drug Inc 7-chloro-4-[5-(n-ethyl-n-2-hydroxyethylamino)-2-pentyl] aminoquinoline, its acid addition salts, and method of preparation
US5021426A (en) * 1990-02-26 1991-06-04 Merck & Co., Inc. Method of traeting malaria with cyproheptadine derivatives

Also Published As

Publication number Publication date
SK98793A3 (en) 1994-09-07
FI934051A0 (fi) 1993-09-15
IL107004A0 (en) 1993-12-28
MX9305621A (es) 1994-03-31
PH30153A (en) 1997-01-21
CZ192393A3 (en) 1994-03-16
NO933293L (no) 1994-03-16
DE69318783D1 (de) 1998-07-02
MY109822A (en) 1997-08-30
EP0588430B1 (en) 1998-05-27
NO933293D0 (no) 1993-09-15
EP0588430A1 (en) 1994-03-23
ATE166646T1 (de) 1998-06-15
CA2104903A1 (en) 1994-03-16
HU9302613D0 (en) 1993-12-28
NO180677C (no) 1997-05-28
US5314894A (en) 1994-05-24
AU4732693A (en) 1994-03-24
NZ248671A (en) 1995-04-27
NO180677B (no) 1997-02-17
AU7549496A (en) 1997-04-10
FI934051A (fi) 1994-03-16
HUT70025A (en) 1995-09-28
JPH06199801A (ja) 1994-07-19

Similar Documents

Publication Publication Date Title
KR940007002A (ko) (s)-(+)- 하이드록시 클로로퀸
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
KR880012218A (ko) 캘폰 유도체를 사용한 다발성 경화증의 치료방법
DK0705100T3 (da) Terapeutiske substituerede guanidiner
GR3026369T3 (en) Pharmaceutical preparation containing an uricosuric and an excitatory amino acid antagonist.
KR950005323A (ko) 면역조정, 항염증제
ATE181911T1 (de) Neurotensin-aktive substituierte 1- naphthylpyrazol-3-carboxamide, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen
KR960006915A (ko) 췌장염의 치료 조성물
KR890011589A (ko) 벤즈아미드의 용도
ES2080736T3 (es) Uso de 2,3,4,5-tetrahidro-1h-3-benzazepinas en el tratamiento de trastornos neurologicos.
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
DE68929321D1 (de) Therapeutische Anwendungen von 2',5'-Oligoadenylat-Derivaten
KR890003373A (ko) 수면장애 및 우울증 치료에 화합물의 이용
KR890001540A (ko) 심부전증 치료제
ES2152934T3 (es) Desinfectante viricida.
KR920019349A (ko) 불안을 치료하기 위한 r(+)-3-아미노-1-하이드록시-피롤리딘-2-온의 용도
KR880012228A (ko) 천식 치료제
RU93052163A (ru) (s) - (+) - гидроксихлорохин и композиция для лечения
KR900015750A (ko) 불치병 치료 용도
KR920702623A (ko) 진해제
KR880012231A (ko) 스테로이드의 용도
KR890001567A (ko) 디플루니살 및 트로메타민-함유 조성물
KR890001582A (ko) 향류머티스제

Legal Events

Date Code Title Description
N231 Notification of change of applicant
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid